Skip to main navigation
logo
  • Overview
  • Corporate
    • Corporate Profile
    • Management
    • Board of Directors
    • Key Advisors
    • Corporate Governance
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Quarterly Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • IR Contacts

News & Events

News Releases

News Releases

  • All
  • 2022
  • 2021
  • 2020
  • 2019
2022.05.12
Adagene to Participate in Investor Conferences in May and June
2022.04.08
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
2022.03.31
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
2022.03.16
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
2022.03.08
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 1 - 5 of 46

Shareholder Tools

  • © 2022 Adagene Inc.

Footer Bottom

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn